Clevudine

Clevudine (L-FMAU), a nucleoside analog of the unnatural L-configuration, has potent anti-HBV activity with long half-life, low toxicity. Clevudine is a non-competitive inhibitor that is not incorporated into the viral DNA but rather binds to the polymerase. Clevudine is active against cowpox virus respiratory infection in mice[1][2][3].

Product Specifications

CAS Number

[163252-36-6]

Product Name Alternative

L-FMAU

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

DNA/RNA Synthesis; HBV; Orthopoxvirus

Type

Oligonucleotides

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Clevudine.html

Purity

99.93

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL

Smiles

O[C@@H]1[C@@H](F)[C@@H](N2C(NC(C(C)=C2)=O)=O)O[C@H]1CO

Molecular Formula

C10H13FN2O5

Molecular Weight

260.22

Precautions

H302, H315, H319, H335

References & Citations

[1]Asselah T, et al. Clevudine: a promising therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs. 2008;17 (12) :1963-1974.|[2]Yoo BC, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology. 2007;46 (4) :1041-1048.|[3]Smee DF, et, al. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother. 2008;19 (3) :115-24.